Table 1.
16S | MG | ITS | |
---|---|---|---|
Bacteria | |||
Firmicutes | |||
Treatment | 0.56 | 0.24 | – |
Age | 0.93 | 0.64 | – |
Treatment*Age | 0.51 | 0.00 | – |
Proteobacteria | |||
Treatment | 13.61** | 38.92*** | – |
Age | 0.74 | 1.33 | – |
Treatment*Age | 10.08* | 0.18 | – |
Actinobacteria | |||
Treatment | 8.68* | 24.67** | – |
Age | 0.00 | 0.00 | – |
Treatment*Age | 0.27 | 0.05 | – |
Bacteroidetes | |||
Treatment | 0.33 | 3.14 | – |
Age | 0.27 | 7.80* | – |
Treatment*Age | 2.19 | 0.24 | – |
Fungi | |||
Ascomycota | |||
Treatment | – | 0.76 | 0.40 |
Age | – | 0.98 | 1.30 |
Treatment*Age | – | 1.01 | 1.38 |
Basidiomycota | |||
Treatment | – | 0.95 | 0.32 |
Age | – | 1.01 | 1.17 |
Treatment*Age | – | 0.99 | 1.06 |
The significance of LMs was estimated using ANOVA of Treatment III with Satterthwaite approximation for 1 degree of freedom. For each test, we report the relevant F statistic (F) and significance [P(>F)] as
p < 0.05,
p < 0.01,
p < 0.001. MG, metagenomic analysis.